4.6 Article

Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid-β-induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 291, 期 4, 页码 1719-1734

出版社

ELSEVIER
DOI: 10.1074/jbc.M115.666529

关键词

-

资金

  1. National Institutes of Health [NS041787]
  2. Japan Society for the Promotion of Science
  3. Uehara Memorial Foundation

向作者/读者索取更多资源

Diverse lines of evidence suggest that amyloid-beta (A beta) peptides causally contribute to the pathogenesis of Alzheimer disease (AD), the most frequent neurodegenerative disorder. However, the mechanisms by which A beta impairs neuronal functions remain to be fully elucidated. Previous studies showed that soluble A beta oligomers interfere with synaptic functions by depleting NMDA-type glutamate receptors (NMDARs) from the neuronal surface and that overexpression of the receptor tyrosine kinase EphB2 can counteract this process. Through pharmacological treatments and biochemical analyses of primary neuronal cultures expressing wild-type or mutant forms of EphB2, we demonstrate that this protective effect of EphB2 depends on its PDZ-binding motif and the presence of neuronal activity but not on its kinase activity. We further present evidence that the protective effect of EphB2 may be mediated by the AMPA-type glutamate receptor subunit GluA2, which can become associated with the PDZ-binding motif of EphB2 through PDZ domain-containing proteins and can promote the retention of NMDARs in the membrane. In addition, we show that the A beta-induced depletion of surface NMDARs does not depend on several factors that have been implicated in the pathogenesis of A beta-induced neuronal dysfunction, including aberrant neuronal activity, tau, prion protein (PrPC), and EphB2 itself. Thus, although EphB2 does not appear to be directly involved in the A beta-induced depletion of NMDARs, increasing its expression may counteract this pathogenic process through a neuronal activity-and PDZ-dependent regulation of AMPA-type glutamate receptors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Neurosciences

Tau Reduction Prevents Key Features of Autism in Mouse Models

Chao Tai, Che-Wei Chang, Gui-Qiu Yu, Isabel Lopez, Xinxing Yu, Xin Wang, Weikun Guo, Lennart Mucke

NEURON (2020)

Article Biology

Long-term potentiation is independent of the C-tail of the GluA1 AMPA receptor subunit

Javier Diaz-Alonso, Wade Morishita, Salvatore Incontro, Jeffrey Simms, Julia Holtzman, Michael Gill, Lennart Mucke, Robert C. Malenka, Roger A. Nicoll

Review Multidisciplinary Sciences

Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies

Che-Wei Chang, Eric Shao, Lennart Mucke

Summary: Evidence suggests that the protein tau plays a role in the pathogenesis of various brain disorders, but the specific functions and contributions of abnormal tau species in different disease models pose challenges to developing effective therapeutic strategies.

SCIENCE (2021)

Article Neurosciences

Phenotypic differences between the Alzheimer's disease-related hAPP-J20 model and heterozygous Zbtb20 knockout mice

Daniel R. Gulbranson, Kaitlyn Ho, Gui-Qiu Yu, Xinxing Yu, Melanie Das, Eric Shao, Daniel Kim, Weiping J. Zhang, Krishna Choudhary, Reuben Thomas, Lennart Mucke

Summary: This study demonstrates that the insertional mutation in hAPP-J20 mice does not account for the Alzheimer's disease (AD)-like phenotype of this model. Furthermore, neural development and brain functions are well preserved in Zbtb20(+/-) mice when Zbtb20 levels are reduced by half.

ENEURO (2021)

Article Neurosciences

Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level

Erik C. B. Johnson, E. Kathleen Carter, Eric B. Dammer, Duc M. Duong, Ekaterina S. Gerasimov, Yue Liu, Jiaqi Liu, Ranjita Betarbet, Lingyan Ping, Luming Yin, Geidy E. Serrano, Thomas G. Beach, Junmin Peng, Philip L. De Jager, Vahram Haroutunian, Bin Zhang, Chris Gaiteri, David A. Bennett, Marla Gearing, Thomas S. Wingo, Aliza P. Wingo, James J. Lah, Allan I. Levey, Nicholas T. Seyfried

Summary: This study analyzed the proteomes of over 1,000 brain tissues and identified new protein co-expression modules associated with Alzheimer's disease. These modules were highly conserved across cohorts and brain regions and revealed a proteopathic nature of the disease. The study also found disease-associated modules unique to the proteome, which could serve as potential therapeutic targets and biomarkers for Alzheimer's disease.

NATURE NEUROSCIENCE (2022)

Article Cell Biology

Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation/inhibition ratios, and counteracts network hypersynchrony

Che-Wei Chang, Mark D. Evans, Xinxing Yu, Gui-Qiu Yu, Lennart Mucke

Summary: The protein tau plays a crucial role in brain disorders, and reducing its levels can prevent network hypersynchrony and counteract brain disorders with abnormally increased excitation-inhibition ratios.

CELL REPORTS (2021)

Article Clinical Neurology

Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity A Randomized Clinical Trial

Keith Vossel, Kamalini G. Ranasinghe, Alexander J. Beagle, Alice La, Kasey Ah Pook, Madelyn Castro, Danielle Mizuiri, Susanne M. Honma, Nisha Venkateswaran, Mary Koestler, Wenbo Zhang, Lennart Mucke, Michael J. Howell, Katherine L. Possin, Joel H. Kramer, Adam L. Boxer, Bruce L. Miller, Srikantan S. Nagarajan, Heidi E. Kirsch

Summary: The study demonstrated that treatment with levetiracetam improved spatial memory and executive function tasks in patients with Alzheimer's disease and epileptiform activity, suggesting the need for further assessment of antiseizure approaches in AD.

JAMA NEUROLOGY (2021)

Article Multidisciplinary Sciences

Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis

Hazal Haytural, Rui Benfeitas, Sophia Schedin-Weiss, Erika Bereczki, Melinda Rezeli, Richard D. Unwin, Xusheng Wang, Eric B. Dammer, Erik C. B. Johnson, Nicholas T. Seyfried, Bengt Winblad, Betty M. Tijms, Pieter Jelle Visser, Susanne Frykman, Lars O. Tjernberg

Summary: Through meta-analysis of high-quality proteomic studies, consistent pathological changes in Alzheimer's disease were revealed, particularly involving dysregulation of pathways related to synaptic signaling, oxidative phosphorylation, immune response, and extracellular matrix.

SCIENTIFIC DATA (2021)

Article Multidisciplinary Sciences

Interdependence of neural network dysfunction and microglial alterations in Alzheimer's disease-related models

Melanie Das, Wenjie Mao, Eric Shao, Soniya Tamhankar, Gui-Qiu Yu, Xinxing Yu, Kaitlyn Ho, Xin Wang, Jiaming Wang, Lennart Mucke

Summary: Nonconvulsive epileptiform activity and microglial alterations have been detected in individuals with Alzheimer's disease (AD) and related mouse models. Suppressing epileptiform activity reversed or prevented aberrant microglial gene expression, including modulation of key factors like TREM2, which seems to support microglial activities counteracting network dysfunction.

ISCIENCE (2021)

Article Cell Biology

TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model

Eric Shao, Che-Wei Chang, Zhiyong Li, Xinxing Yu, Kaitlyn Ho, Michelle Zhang, Xin Wang, Jeffrey Simms, Iris Lo, Jessica Speckart, Julia Holtzman, Gui-Qiu Yu, Erik D. Roberson, Lennart Mucke

Summary: This study found that reducing TAU in excitatory neurons can alleviate various brain dysfunctions, including epilepsy and overactivation of the phosphoinositide 3-kinase-AKT-mammalian target of rapamycin pathway, in a mouse model of Dravet syndrome. Additionally, treatment with a TAU-lowering antisense oligonucleotide had similar therapeutic effects.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Chemistry, Medicinal

Discovery of Potent and Selective Dual Leucine Zipper Kinase/ Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis

Robert A. Craig II, Brian M. Fox, Cheng Hu, Katrina W. Lexa, Maksim Osipov, Arun P. Thottumkara, Martin Larhammar, Takashi Miyamoto, Anil Rana, Lesley A. Kane, Ernie Yulyaningsih, Hilda Solanoy, Hoang Nguyen, Roni Chau, Timothy Earr, Yuji Kajiwara, Daniel Fleck, Anthony Lucas, Patrick C. G. Haddick, Ryan H. Takahashi, Vincent Tong, Jing Wang, Mark J. Canet, Suresh B. Poda, Kimberly Scearce-Levie, Ankita Srivastava, Zachary K. Sweeney, Musheng Xu, Rui Zhang, Jianrong He, Yanan Lei, Zheng Zhuo, Javier de Vicente

Summary: This study identified novel inhibitors of dual leucine zipper kinase/leucine zipper-bearing kinase through drug design approaches. The identified inhibitor demonstrated excellent pharmacokinetic properties and therapeutic potential in in vivo and in vitro studies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Clinical Neurology

Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome

Eric B. Dammer, Lingyan Ping, Duc M. Duong, Erica S. Modeste, Nicholas T. Seyfried, James J. Lah, Allan Levey, Erik C. B. Johnson

Summary: Robust and accessible biomarkers are urgently needed for the study of Alzheimer's disease. The study found correlations between protein markers in CSF and plasma, with greater variability in plasma. Proteomic analysis revealed changes in protein co-expression modules related to autophagy, ubiquitination, sugar metabolism, and other processes.

ALZHEIMERS RESEARCH & THERAPY (2022)

Article Multidisciplinary Sciences

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease

Caroline M. Watson, Eric B. Dammer, Lingyan Ping, Duc M. Duong, Erica Modeste, E. Kathleen Carter, Erik C. B. Johnson, Allan I. Levey, James J. Lah, Blaine R. Roberts, Nicholas T. Seyfried

Summary: Alzheimer's disease (AD) is the most common form of dementia, and CSF beta-amyloid, total Tau, and phosphorylated Tau (pTau) are sensitive and specific biomarkers for diagnosis. However, these biomarkers do not capture the complex changes in AD brain beyond amyloid and Tau pathologies. This study used SRM-MS with isotopically labeled standards to quantify CSF protein biomarkers, identifying proteins that could distinguish AD stages and cognitive impairment.

SCIENTIFIC DATA (2023)

Article Cell Biology

A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease

Rafi Haque, Caroline M. Watson, Jiaqi Liu, E. Kathleen Carter, Duc M. Duong, James J. Lah, Aliza P. Wingo, Blaine R. Roberts, Erik C. B. Johnson, Andrew J. Saykin, Leslie M. Shaw, Nicholas T. Seyfried, Thomas S. Wingo, Allan I. Levey

Summary: This study developed a reliable and high-throughput mass spectrometry assay to detect 48 key proteins in cerebrospinal fluid (CSF), and found that this panel of proteins performed at least as well as existing biomarkers in predicting clinical diagnosis, brain imaging results, cognitive decline, and dementia severity in Alzheimer's disease. Combining this panel with existing biomarkers significantly improved diagnostic accuracy and prediction of disease progression.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Cell Biology

CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

Marta del Campo, Carel F. W. Peeters, Erik C. B. Johnson, Lisa Vermunt, Yanaika S. Hok-A-Hin, Mirrelijn van Nee, Alice Chen-Plotkin, David J. Irwin, William T. Hu, James J. Lah, Nicholas T. Seyfried, Eric B. Dammer, Gonzalo Herradon, Lieke H. Meeter, John van Swieten, Daniel Alcolea, Alberto Lleo, Allan I. Levey, Afina W. Lemstra, Yolande A. L. Pijnenburg, Pieter J. Visser, Betty M. Tijms, Wiesje M. van der Flier, Charlotte E. Teunissen

Summary: This study identifies specific dysregulated CSF proteins along the AD continuum, reflecting the multifactorial nature of disease progression. Some of these dysregulated proteins can be used as biomarkers for the diagnosis and clinical trials of AD.

NATURE AGING (2022)

暂无数据